Biotech Values

[genisi]

If tested positive for ALK then I would start with Xalkori, and upon progression I would vote for an anti PD-1. Data from BMS's phase I trial of nivolumab + combo of different chemo regimens, in chemo naïve NSCLC were really impressive. Should have activity in both squamous and nonsquamous histologies but PD-L1 is probably a critical predictor for nivo activity. Tough to say if with EGFR mutations to start with Tarceva or anti PD-1. I guess it depends on PD-L1 status and ability to enroll in a clinical trial. From my experience the best way to expedite the process to get into trials faster is to use personal contacts with the trial investigator.